Description: Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.
Home Page: www.xbrane.com
Retzius väg 8
Solna,
171 65
Sweden
Phone:
46 7 60 34 67 33
Officers
| Name | Title |
|---|---|
| Mr. Martin Åmark | Chief Exec. Officer |
| Mr. Siavash Bashiri | COO, Head of Biosimilars & Deputy CEO |
| Associate Prof. Jan-Willem De Gier | Co-Founder |
| Dr. Samuel Wagner Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Ms. Anette Lindqvist | CFO & Head of Investor Relations |
| Dr. David Vikström | Chief Technology Officer |
| Mr. Erik Domines | Gen. Counsel |
| Ms. Nina Ivers | Head of HR |
| Ms. Dina Jurman | Head of Clinical Affairs |
| Ms. Maria Edebrink | Head of Regulatory Affairs & Quality Assurance |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.4919 |
| Price-to-Sales TTM: | 75.0911 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 74 |